SEPTInvestingStart Free

FBRX SCHEDULE 13G/A: SEC filing

MPM BioImpact LLC

Filed with the SEC on · accession 0001687078-26-000026

FBRX filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 13, 2026. A report the company filed with the SEC (the US market regulator).

Summary of the filing

MPM BioImpact LLC filed an amended Schedule 13G indicating it no longer beneficially owns any shares of Forte Biosciences, Inc., reporting 0% ownership as of September 30, 2026.

For details, click here →

Key details

Shares beneficially owned$0
Percent of class owned$0
Filer / former beneficial ownerMPM BioImpact LLC
IssuerForte Biosciences, Inc.
Chief financial officer, mpm bioimpact llcChristopher Wolf

✦ Ask GOAX AI about this filing — what it means for FBRX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for FBRX?

Click here

Frequently asked questions

What did FBRX file with the SEC on Nov 13, 2026?

FBRX filed a SCHEDULE 13G/A (SEC filing). MPM BioImpact LLC filed an amended Schedule 13G indicating it no longer beneficially owns any shares of Forte Biosciences, Inc., reporting 0% ownership as of September 30, 2026.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

Other FBRX SEC filings

Get alerts when FBRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
FBRX overviewFBRX analysisFBRX newsLatest SEC filings